Results 141 to 150 of about 6,944 (246)

Real‐world persistence and dose titration of GLP‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3386-3395, April 2026.
Abstract Aims Real‐world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP‐1 receptor agonist (GLP‐1RA) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, obesity status, cardiovascular disease (CVD) history, and sex assigned at birth.
Franziska S. Ulrich, Nicola Napoli, Morten Frost Nielsen, Andrea M. Burden   +3 more
wiley   +1 more source

Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance [PDF]

Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli‐Ducci, Daniele Torella, Isabella Leo   +9 more
openalex   +1 more source

Glucagon‐Like Peptide 1 Receptor Agonists, Sodium‐Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Volume 78, Issue 3, Page 654-664, March 2026.
Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
GLP‐1 receptor agonists significantly improved weight loss, BMI, HbA1c, and cholesterol in patients after bariatric surgery, supporting their role in enhancing postoperative metabolic outcomes. ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) have demonstrated promising effects in promoting weight loss and improving metabolic ...
Abdur Rafay Bilal, Muhammad Ibrahim, S. M. Washaqul Arfin, Abdur Raheem Bilal, Rahul Balach, Shaheer Qureshi, Hateem Gaba, Peter Collins, Raheel Ahmed, Saad Ahmed Waqas   +9 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review

Matt Thomas, Svetlana Mastitskaya, Samuel Parker, Ruth Cookson, Lucy Holmes, Aidan Marsh, Aravind Ramesh, Sarah Rudd, Mario Teo, Alex Mortimer   +9 more
openalex   +1 more source

GLP-1RAs in patients with psoriasis

Hormones
Ioanna A. Paschou, Evangelia Sali, Stavroula A. Paschou, Theodora Psaltopoulou, Electra Nicolaidou, Alexander J. Stratigos   +5 more
openaire   +3 more sources

Comparing SGLT2i and Other Oral Antidiabetic Drugs as Dual Therapy Add‐On to Metformin in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
This systematic literature review and meta‐analysis compared sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) against other metformin‐containing oral dual‐therapies (ODTs) in type 2 diabetes mellitus. SGLT‐2i plus metformin exhibited overall comparable efficacy and safety, with a lower risk of hypoglycaemia and greater weight reduction than other ...
Yuhang Ma, Yi Lin, Xiaoying Ding, Yongde Peng   +3 more
wiley   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

Obesity, Volume 34, Issue 3, Page 565-578, March 2026.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden, Maria A. Oquendo, Robert F. Kushner, Dachuang Cao, Chrisanthi A. Karanikas, Afton Kechter, Madhumita A. Murphy   +6 more
wiley   +1 more source

GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites. [PDF]

Nutrients
Gong B, Shi Z, Qi J, Wang F, Chen G, Su H.   +5 more
europepmc   +1 more source

Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use. [PDF]

J Endocr Soc
Ayo-Ajibola O, Jung T, Razura DE, Gallagher TJ, Lin ME, Angell TE, Kwon DI.   +6 more
europepmc   +1 more source